← Zhuhai Rundu Pharmaceutical overview

Zhuhai Rundu Pharmaceutical vs Sichuan Kelun Pharmaceutical: why the prices moved differently

Weekly · monthly · quarterly news summaries, side by side in time

Zhuhai Rundu Pharmaceutical Co Ltd Class A (002923.CS)

Q3 2026
▲2▼1

Rundu swings to profit as new heart drugs win approvals

  • New hypertension drug approvals widen product line Rundu won Chinese approval for azilsartan tablets and, separately, marketing approval for amlodipine besylate, the key ingredient in a common blood-pressure medicine. Both add to its heart and stroke product range, supporting future sales and its ingredient-to-finished-pill chain.

    These regulatory approvals are genuinely new and expand the products the company can sell.

  • Innovative heart-imaging drug gets provincial support Rundu's first-in-class higenamine hydrochloride injection was picked for Guangdong's innovative drug catalog. That status brings provincial policy support for promoting and selling the product, which should help it reach more hospitals and patients over time.

    This is a new regulatory win that could lift sales of a high-value innovative product.

  • Controlling shareholder still heavily pledged Controlling shareholder Li Xi released 2.15 million pledged shares, but 97.2% of his stake remains pledged. Heavy pledging can signal personal financial strain and, if shares fall, risks forced selling that would weigh on the stock price.

    This is the main counterweight to the good news and a real risk investors should weigh.

August 2026
▲2▼1

Rundu swings to profit as new heart drugs win approvals

  • New hypertension drug approvals widen product line Rundu won Chinese approval for azilsartan tablets and, separately, marketing approval for amlodipine besylate, the key ingredient in a common blood-pressure medicine. Both add to its heart and stroke product range, supporting future sales and its ingredient-to-finished-pill chain.

    These regulatory approvals are genuinely new and expand the products the company can sell.

  • Innovative heart-imaging drug gets provincial support Rundu's first-in-class higenamine hydrochloride injection was picked for Guangdong's innovative drug catalog. That status brings provincial policy support for promoting and selling the product, which should help it reach more hospitals and patients over time.

    This is a new regulatory win that could lift sales of a high-value innovative product.

  • Controlling shareholder still heavily pledged Controlling shareholder Li Xi released 2.15 million pledged shares, but 97.2% of his stake remains pledged. Heavy pledging can signal personal financial strain and, if shares fall, risks forced selling that would weigh on the stock price.

    This is the main counterweight to the good news and a real risk investors should weigh.

Latest
▲2▼1

Rundu swings to profit as new heart drugs win approvals

  • New hypertension drug approvals widen product line Rundu won Chinese approval for azilsartan tablets and, separately, marketing approval for amlodipine besylate, the key ingredient in a common blood-pressure medicine. Both add to its heart and stroke product range, supporting future sales and its ingredient-to-finished-pill chain.

    These regulatory approvals are genuinely new and expand the products the company can sell.

  • Innovative heart-imaging drug gets provincial support Rundu's first-in-class higenamine hydrochloride injection was picked for Guangdong's innovative drug catalog. That status brings provincial policy support for promoting and selling the product, which should help it reach more hospitals and patients over time.

    This is a new regulatory win that could lift sales of a high-value innovative product.

  • Controlling shareholder still heavily pledged Controlling shareholder Li Xi released 2.15 million pledged shares, but 97.2% of his stake remains pledged. Heavy pledging can signal personal financial strain and, if shares fall, risks forced selling that would weigh on the stock price.

    This is the main counterweight to the good news and a real risk investors should weigh.

Sichuan Kelun Pharmaceutical Co Ltd (002422.CS)

Q3 2026
▲3▼1

Kelun's profit rises on drug wins and buybacks, but bribery claim and pledges weigh

  • New ADC drug enters clinical trials A Kelun subsidiary won Chinese approval to start human testing of SKB565, a new dual-payload ADC for advanced solid tumors. It is the first of its kind from Kelun Biotech, and success could add a valuable future growth engine, though it is years from sales.

    Shows pipeline progress that can lift long-term growth expectations for the stock.

  • National procurement wins boost sales outlook Kelun and its units won tentative selection for more than ten products in China's 12th national bulk-buy drug round, including heart and cancer medicines. Winning means guaranteed hospital sales volumes, supporting revenue even if prices are lower.

    Directly increases expected product demand and market share, a core earnings driver.

  • Profit grows and dividend plus buyback support stock First-half net profit rose 12.7% to 1.128 billion yuan, with second-quarter profit up 48% from the prior quarter, despite slightly lower revenue. The company also plans a cash dividend and has been buying back shares, signaling confidence and returning cash to holders.

    Earnings growth and shareholder returns are the main fundamental supports for the share price.

  • Bribery claim and owner pledges create risk A whistleblower letter alleged commercial bribery tied to a key Kelun drug; the subsidiary denies it and threatens legal action. Separately, controlling shareholder Liu Gexin added to pledged shares for personal funding. Both raise uncertainty and could pressure the stock if they worsen.

    These are the main counterweights that could hurt sentiment and valuation.

September 2026
▲3▼1

Kelun's profit rises on drug wins and buybacks, but bribery claim and pledges weigh

  • New ADC drug enters clinical trials A Kelun subsidiary won Chinese approval to start human testing of SKB565, a new dual-payload ADC for advanced solid tumors. It is the first of its kind from Kelun Biotech, and success could add a valuable future growth engine, though it is years from sales.

    Shows pipeline progress that can lift long-term growth expectations for the stock.

  • National procurement wins boost sales outlook Kelun and its units won tentative selection for more than ten products in China's 12th national bulk-buy drug round, including heart and cancer medicines. Winning means guaranteed hospital sales volumes, supporting revenue even if prices are lower.

    Directly increases expected product demand and market share, a core earnings driver.

  • Profit grows and dividend plus buyback support stock First-half net profit rose 12.7% to 1.128 billion yuan, with second-quarter profit up 48% from the prior quarter, despite slightly lower revenue. The company also plans a cash dividend and has been buying back shares, signaling confidence and returning cash to holders.

    Earnings growth and shareholder returns are the main fundamental supports for the share price.

  • Bribery claim and owner pledges create risk A whistleblower letter alleged commercial bribery tied to a key Kelun drug; the subsidiary denies it and threatens legal action. Separately, controlling shareholder Liu Gexin added to pledged shares for personal funding. Both raise uncertainty and could pressure the stock if they worsen.

    These are the main counterweights that could hurt sentiment and valuation.

Latest
▲3▼1

Kelun's profit rises on drug wins and buybacks, but bribery claim and pledges weigh

  • New ADC drug enters clinical trials A Kelun subsidiary won Chinese approval to start human testing of SKB565, a new dual-payload ADC for advanced solid tumors. It is the first of its kind from Kelun Biotech, and success could add a valuable future growth engine, though it is years from sales.

    Shows pipeline progress that can lift long-term growth expectations for the stock.

  • National procurement wins boost sales outlook Kelun and its units won tentative selection for more than ten products in China's 12th national bulk-buy drug round, including heart and cancer medicines. Winning means guaranteed hospital sales volumes, supporting revenue even if prices are lower.

    Directly increases expected product demand and market share, a core earnings driver.

  • Profit grows and dividend plus buyback support stock First-half net profit rose 12.7% to 1.128 billion yuan, with second-quarter profit up 48% from the prior quarter, despite slightly lower revenue. The company also plans a cash dividend and has been buying back shares, signaling confidence and returning cash to holders.

    Earnings growth and shareholder returns are the main fundamental supports for the share price.

  • Bribery claim and owner pledges create risk A whistleblower letter alleged commercial bribery tied to a key Kelun drug; the subsidiary denies it and threatens legal action. Separately, controlling shareholder Liu Gexin added to pledged shares for personal funding. Both raise uncertainty and could pressure the stock if they worsen.

    These are the main counterweights that could hurt sentiment and valuation.